Understanding OUR Cytokine-Based Immunotherapy Candidates Our commitment extends to advancing a robust portfolio of programs targeted at expanding the horizons of cytokine-based immunotherapy, specifically for cancers where treatment possibilities remain limited. Use the links below to learn far more about our portfolio of cytokine-based immunotherapy candidates. Explore Our Pipeline https://financefeeds.com/six-welcomes-nxtassets-as-18th-copyright-etp-issuer/